Product pipeline


Novacta is developing NVB302 for the treatment of C. difficile infection. NVB302 is not absorbed, resulting in optimal concentration in the GI tract which is the site of infection. It is highly selective for C. difficile over other members of the normal gut flora, which may translate into improved therapeutic properties (especially recurrence). It also has an excellent resistance prognosis. NVB302 has successfully completed a phase I clinical trial in healthy volunteers. The NVB302 programme is supported by the Wellcome Trust.

Novacta's programmes for systemic treatment of infections caused by Gram-positive and Gram-negative bacteria are licensed to Cantab Anti-Infectives.